Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody
T Dreier, G Lorenczewski, C Brandl… - … journal of cancer, 2002 - Wiley Online Library
A recent study reported on an anti-CD19/anti-CD3 singlechain bispecific antibody (bscCD19xCD3)
exhibiting high activity against human B lymphoma cell lines (Löffler et al., Blood …
exhibiting high activity against human B lymphoma cell lines (Löffler et al., Blood …
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a …
…, M Grun, B Schlereth, G Lorenczewski… - The Journal of …, 2003 - journals.aai.org
We have recently demonstrated that a recombinant single-chain bispecific Ab construct,
bscCD19xCD3, in vitro induces rapid B lymphoma-directed cytotoxicity at picomolar …
bscCD19xCD3, in vitro induces rapid B lymphoma-directed cytotoxicity at picomolar …
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS-and BRAF-mutated colorectal cancer cells
…, O Thomas, G Lorenczewski… - Proceedings of the …, 2010 - National Acad Sciences
Epidermal growth factor receptor (EGFR)-specific monoclonal antibodies predominantly
inhibit colorectal cancer (CRC) growth by interfering with receptor signaling. Recent analyses …
inhibit colorectal cancer (CRC) growth by interfering with receptor signaling. Recent analyses …
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific …
B Schlereth, I Fichtner, G Lorenczewski, P Kleindienst… - Cancer research, 2005 - AACR
Bispecific T-cell engager (BiTE) are a class of bispecific single-chain antibodies that can very
effectively redirect cytotoxic T cells for killing of tumor target cells. Here, we have assessed …
effectively redirect cytotoxic T cells for killing of tumor target cells. Here, we have assessed …
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
…, C Quadt, T Dreier, P Kufer, G Lorenczewski… - Cancer Immunology …, 2006 - Springer
BscCD19xCD3 is a bispecific single-chain antibody construct with exceptional cytotoxic
potency in vitro and in vivo. Here, we have investigated the biological activity of bscCD19xCD3 …
potency in vitro and in vivo. Here, we have investigated the biological activity of bscCD19xCD3 …
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3
…, P Lutterbuese, L Parr, L Petersen, G Lorenczewski… - Cancer research, 2008 - AACR
EpCAM (CD326) is one of the most frequently and highly expressed tumor-associated antigens
known and recently has also been found on cancer stem cells derived from human breast…
known and recently has also been found on cancer stem cells derived from human breast…
[HTML][HTML] Generation of a half-life extended anti-CD19 BiTE® antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies
G Lorenczewski, M Friedrich, R Kischel, C Dahlhoff… - Blood, 2017 - Elsevier
CD19 is an immunoglobulin family member expressed ubiquitously on B cell lineage cells,
from the pre-B cell to the mature B cell stage, until downregulation during terminal …
from the pre-B cell to the mature B cell stage, until downregulation during terminal …
Preclinical assessment of AMG 596, a bispecific T-cell engager (BiTE) immunotherapy targeting the tumor-specific antigen EGFRvIII
…, O Thomas, M Balazs, J Wahl, G Lorenczewski… - Molecular Cancer …, 2021 - AACR
AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development
for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor …
for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor …
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
M Amann, G Lorenczewski, K Brischwein… - Journal of …, 2009 - journals.lww.com
muS110 is a BiTE antibody bispecific for murine EpCAM (CD326) and murine CD3. MT110,
its human-specific analog, is in a clinical phase 1 trial for treatment of patients with …
its human-specific analog, is in a clinical phase 1 trial for treatment of patients with …
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
…, P Kleindienst, I Fichtner, G Lorenczewski… - Cancer Immunology …, 2006 - Springer
Bispecific single-chain antibody constructs specific for human CD3 have been extensively
studied for antitumor activity in human xenograft models using severe combined …
studied for antitumor activity in human xenograft models using severe combined …